Management of the hematologic complications of hepatitis C therapy.
Consensus guidelines are in place for treating chronic hepatitis C virus infection. This article highlights some of the hematologic complications of hepatitis C therapy. Management options are presented.
Sulkowski
Mark S
MS
Viral Hepatitis Center, Johns Hopkins University School of Medicine, 600 North Wolfe Street, 1830 Building, Room 448, Baltimore, MD 21287, USA. msulkows@jhmi.edu
D000740:Anemia / Q000139:chemically induced / Q000628:therapy; D000998:Antiviral Agents / Q000009:adverse effects*; D001853:Bone Marrow / Q000187:drug effects; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000627:therapeutic use; D006402:Hematologic Diseases / Q000139:chemically induced* / Q000628:therapy*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects*; D009503:Neutropenia / Q000139:chemically induced / Q000628:therapy; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*; D013921:Thrombocytopenia / Q000139:chemically induced / Q000628:therapy
D000998:Antiviral Agents; D007370:Interferon Type I; D011994:Recombinant Proteins; D004921:Erythropoietin; D012254:Ribavirin; D000068817:Epoetin Alfa